Skip to main content

Table 1 Reporting of the core outcomes within the rheumatoid arthritis core outcomes set

From: Outcome measures in rheumatoid arthritis randomised trials over the last 50 years

  Seven core outcomes (trials <52 weeks) Eight core outcomes (trials ≥52 weeks)
Intervention classification % measured (Pre-RA COS) % measured (Post-RA COS) % measured (Pre-RA COS) % measured (Post-RA COS)
Pharmacological     
DMARD/SAARD 27 (9/33) 85 (17/20) 25 (3/12) 53 (9/17)
SMARD 4 (2/50) 29 (5/17) 0 (0/2) 0 (0/2)
Glucocorticoids 100 (1/1) - 0 (0/1) 40 (4/10)
Biologics - 93 (26/28) - 64 (7/11)
Non-pharmacological     
Alternative therapies 15 (2/13) 88 (7/8) 0 (0/2) 0 (0/2)
Assistive technology - 0 (0/1) - -
Diet 20 (1/5) 57 (4/7) 0 (0/1) 100 (1/1)
Exercise 0 (0/3) 0 (0/2) 0 (0/2) 0 (0/1)
Rehabilitation 0 (0/47) 4 (1/27) 0 (0/8) 0 (0/13)
Surgery - - - 0 (0/3)
  1. DMARD, disease-modifying anti-rheumatic drugs; pre-RA COS, randomised trials published up to 1994; post-RA COS, randomised trials published after 1994; SAARD, slow-acting anti-rheumatic drugs; SMARD, symptom-modifying anti-rheumatic drugs.